AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2017
Nov 18, 2017
31289_dirs_2017-11-17_36a9d817-09ab-44c1-8b4b-4f43fd14a106.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2017-11-17
Reporting Person: LAMATTINA JOHN L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-11-17 | Common Stock | M | 4000 | $10.12 | Acquired | 24956 | Direct |
| 2017-11-17 | Common Stock | S | 4000 | $139.79 | Disposed | 20956 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-11-17 | Non-Qualified Stock Option (right to buy) | $10.12 | M | 4000 | Disposed | 2021-06-01 | Common Stock (4000) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.75 to $139.79, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and will fully vest on the first anniversary of the grant date.